Arcellx, Inc. (ACLX)
Arcellx, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Redwood City, MD, US. The stock last traded at $115.07, up 0.02% on the session, giving a market capitalisation of $6.73B. On trailing twelve-month figures it carries a trailing P/E of -28.27, a net margin of -1027.3%. Its beta of 0.25 implies it has historically moved less than the broad market.
Arcellx, Inc. is a clinical-stage biotechnology enterprise dedicated to pioneering immunotherapeutic solutions for patients battling cancer and other intractable diseases. A cornerstone of their pipeline is CART-ddBCMA, an advanced ddCAR product candidate currently undergoing a Phase 1 clinical trial. This investigational treatment targets individuals suffering from relapsed or refractory multiple myeloma (MM). Beyond their lead candidate, Arcellx is also advancing ACLX-001, an immunotherapy composed of ARC-T cells and bi-valent SparX proteins engineered to combat r/r MM by targeting BCMA. Their development efforts extend to ACLX-002 and ACLX-003, designed to address relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), alongside a broader portfolio of additional AML/MDS candidates and programs focused on solid tumors. The company, headquartered in Gaithersburg, Maryland, was established in 2014. It operated as Encarta Therapeutics, Inc. before adopting its current name, Arcellx, Inc., in January 2016.
Arcellx, Inc. is most often compared with the following Healthcare names: